Page last updated: 2024-10-30

memantine and Tauopathies

memantine has been researched along with Tauopathies in 4 studies

Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.

Research Excerpts

ExcerptRelevanceReference
"The pharmacological treatment of dementias aims to improve cognitive deficits, activities of daily living and behavioural and psychiatric symptoms."2.45[Antidementia drugs]. ( Müller-Spahn, F; Sollberger, D; Wollmer, MA, 2009)
"Early-onset dementia has a devastating impact on families and rids its victims of their most productive and rewarding years."2.44New approaches to the treatment of frontotemporal lobar degeneration. ( Miller, BL; Vossel, KA, 2008)
"Memantine was used at a clinically relevant dose (20 mg daily oral administration) from 4 (asymptomatic phase) to 10 (mild cognitive impairment phase) months of age."1.72Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia. ( Alves, S; Audrain, M; Billard, JM; Braudeau, J; Cartier, N; Dutar, P; Fol, R; Orefice, NS; Potier, B; Souchet, B; Tada, S, 2022)
"Background Tauopathies, including Alzheimer's disease (AD), are multifactorial diseases with strong phenotypic and genetic heterogeneity."1.51Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride. ( Gasiorowska, A; Koss, DJ; Mietelska-Porowska, A; Niewiadomska, G; Palasz, E; Riedel, G, 2019)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Souchet, B1
Audrain, M1
Alves, S1
Fol, R1
Tada, S1
Orefice, NS1
Potier, B1
Dutar, P1
Billard, JM1
Cartier, N1
Braudeau, J1
Mietelska-Porowska, A1
Gasiorowska, A1
Palasz, E1
Koss, DJ1
Riedel, G1
Niewiadomska, G1
Vossel, KA1
Miller, BL1
Müller-Spahn, F1
Sollberger, D1
Wollmer, MA1

Reviews

2 reviews available for memantine and Tauopathies

ArticleYear
New approaches to the treatment of frontotemporal lobar degeneration.
    Current opinion in neurology, 2008, Volume: 21, Issue:6

    Topics: Animals; Dementia; DNA-Binding Proteins; Excitatory Amino Acid Antagonists; Humans; Intercellular Si

2008
[Antidementia drugs].
    Therapeutische Umschau. Revue therapeutique, 2009, Volume: 66, Issue:6

    Topics: Aged; Alzheimer Disease; Amyloidosis; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Dose-

2009

Other Studies

2 other studies available for memantine and Tauopathies

ArticleYear
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia.
    The journal of prevention of Alzheimer's disease, 2022, Volume: 9, Issue:2

    Topics: Alzheimer Disease; Animals; Humans; Memantine; Rats; Tauopathies

2022
Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride.
    Journal of neuroscience methods, 2019, 05-01, Volume: 319

    Topics: Alzheimer Disease; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Lithium Chloride; Male;

2019